ArticlePloS one2010
Profile of acute infectious markers in sporadic hepatitis E.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- The silent spread of Hepatitis E in India - from epidemiological insight to public health action: a comprehensive review.Infection · 2026Review
- Extended Duration of Anti-HEV IgM Seropositivity in Asymptomatic Blood Donors: Implications for Transfusion Safety.Viruses · 2026Article
- Performance of Elecsys Anti-HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Population-Based Estimates of Hepatitis E Virus-Associated Mortality in Bangladesh.The Journal of infectious diseases · 2025Article
- A comprehensive review on seroepidemiology and molecular epidemiology of hepatitis E Virus in Iran.Gastroenterology and hepatology from bed to bench · 2025Review
- Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China.Emerging microbes & infections · 2024Article
- Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Hepatitis E virus in the Kathmandu Valley: Insights from a representative longitudinal serosurvey.PLoS neglected tropical diseases · 2024Article
- Kinetics of Hepatitis E Virus Infections in Asymptomatic Persons.Emerging infectious diseases · 2024Article
- An experimental chimeric hepatitis E virus vaccine elicits both local and systemic immune responses.Frontiers in microbiology · 2024Article
- Article
- Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study.Emerging microbes & infections · 2023Article
- Hepatitis E virus neutralization by porcine serum antibodies.Journal of clinical microbiology · 2023Article
- Hepatitis E virus seroprevalence among employees in catering and public place industries in Nanjing, China.Epidemiology and infection · 2023Article
- Development and Evaluation of an Enzyme-Linked Immunosorbent Assay Targeting Rabies-Specific IgM and IgG in Human Sera.Viruses · 2023Article
- Laboratory Diagnosis of HEV Infection.Advances in experimental medicine and biology · 2023Review
- Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan.Microbiology spectrum · 2022Article
- Status of anti-HEV IgG and IgM antibodies among the hemodialysis patients in southwest region of Iran.Iranian journal of microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laboratory diagnosis of acute infection of hepatitis E virus (HEV) is commonly based on the detection of HEV RNA, IgM and/or rising IgG levels. However, the profile of these markers when the patients present have not been well determined. To clarify the extent of misdiagnosed sporadic hepatitis E in the initial laboratory detection, serial sera of 271 sporadic acute hepatitis cases were collected, detected and the dynamics of each acute marker during the illness course were analyzed. 91 confirmed cases of hepatitis E were identified based on the presentation of HEV RNA, IgM or at least 4 fold rising of IgG levels. 21 (23.1%) hepatitis E cases were false negative for the viral RNA and 40 (44.0%) for rising IgG, because occurrence of these markers were confined to acute phase of infection and viremia had already subsided and antibody level peaked when these patients presented. IgM was detected in 82 (90.1%) cases. It is the most prevalent of the three markers, because the antibody persisted until early convalescence. Nine cases negative for IgM were positive for rising IgG and one was also positive for the viral RNA; all of these nine cases showed high avid IgG in their acute phase sera, which indicated re-infection. In summary, it is not practicable to determine the true occurrence of sporadic hepatitis E. Nevertheless, it could be closely approximated by approach using a combination of all three acute markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.